Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 7/20 | 0.45 |
| ▸ | FYN | P06241 | 2/20 | 0.45 |
| ▸ | VCP | P55072 | 2/20 | 0.45 |
| ▸ | EDNRA | P25101 | 2/20 | 0.45 |
| ▸ | YES1 | P07947 | 1/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.45 |
| ▸ | USP7 | Q93009 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | UBE2N | P61088 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ADK | P55263 | 2/20 | 0.41 |
| ▸ | DHPS | P49366 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5763592 | 0.96 | RPS6KA3 (0.44) | RPS6KA3FYNVCPEDNRAYES1 | |
| SCHEMBL4069241 | 0.94 | EDNRA (0.49) | RPS6KA3FYNVCPEDNRAYES1 | |
| SCHEMBL4060847 | 0.81 | EDNRB (0.45) | EDNRAKDM4EMEN1ALDH1A1HPGD | |
| SCHEMBL5764923 | 0.80 | MAPT (0.43) | EDNRAUSP7EDNRBLMNAMAPT | |
| SCHEMBL5762269 | 0.80 | KDR (0.48) | KDM4EALDH1A1HPGDUBE2NKMT2A | |
| SCHEMBL3641648 | 0.79 | EDNRA (0.44) | EDNRAADKDHPSEDNRBKIT | |
| SCHEMBL4062084 | 0.79 | EDNRB (0.56) | EDNRARPS6KB1USP7ADKDHPS | |
| SCHEMBL6293445 | 0.79 | EDNRB (0.46) | RPS6KA3FYNEDNRARPS6KB1USP7 | |
| SCHEMBL4067214 | 0.79 | ALDH1A1 (0.40) | RPS6KA3FYNEDNRARPS6KB1EPHA2 | |
| SCHEMBL4064066 | 0.79 | DRD2 (0.48) | EDNRAALDH1A1ADKEDNRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322624-B1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-21 | — | — | EP | disclosed |
| US-7091201-B2 | Arylalkane-sulfonamides having endothelin-antagonist activity | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-15 | — | — | US | disclosed |
| EP-1309564-B1 | ARYLETHENE-SULFONAMIDES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-06-14 | — | — | EP | disclosed |
| US-6951856-B2 | Arylethene-sulfonamides | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-10-04 | — | — | US | disclosed |
| US-20040102464-A1 | Arylalkane-sulfonamides having endothelin-antagonist activity | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-05-27 | — | — | US | disclosed |
| US-20030220359-A1 | Novel arylethene-sulfonamides | ACTELION PHARMACEUTICALS LTD. (CH) | 2003-11-27 | — | — | US | disclosed |
| EP-1322624-A1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | Actelion Pharmaceuticals Ltd. (CH) | 2003-07-02 | — | — | EP | disclosed |
| EP-1309564-A2 | ARYLETHENE-SULFONAMIDES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002024665-A1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | ACTELION PHARMACEUTICALS LTD (CH) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002008200-A2 | ARYLETHENE-SULFONAMIDES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220359-A1 | Novel arylethene-sulfonamides | EDNRA, ECE2, ECE1 | RPS6KA3 3095/4885FYN 1485/4885VCP 2068/4885 |
| US-20040102464-A1 | Arylalkane-sulfonamides having endothelin-antagonist activity | EDNRA, EDNRB, ECE2 | RPS6KA3 4077/4885FYN 1654/4885VCP 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.